N-PORT filing recap · January 2025

What did ARK Genomic Revolution ETF buy in January 2025?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$1.18B

Positions

Estimated turnover

23.1%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Period in review

The ARK Genomic Revolution ETF exited Moderna and Senti Biosciences entirely in January. It also trimmed a wide range of holdings, including Twist Bioscience, Recursion Pharmaceuticals, Adaptive Biotechnologies, Natera, Veracyte, CareDx, Ionis Pharmaceuticals, Nurix Therapeutics, and Butterfly Network. On the buying side, the fund added substantially to Tempus AI and dramatically increased its Illumina stake, while also adding to Crispr Therapeutics and Absci.

Increased positions

CRSPCrispr Therapeutics AG$76.83Mreported value+65.7K shares+3.7%TEMTempus Ai, Inc.$76.36Mreported value+541.2K shares+68.6%ABSIAbsci Corp$31.93Mreported value+997.2K shares+13.1%ILMNIllumina, Inc.$20.34Mreported value+111.3K shares

Reduced positions

TWSTTwist Bioscience Corporation$111.18Mreported value-314.9K shares-12.9%RXRXRecursion Pharmaceuticals, Inc.$82.24Mreported value-1.46M shares-11.4%GHGuardant Health, Inc.$65.61Mreported value-71.2K shares-4.9%ADPTAdaptive Biotechnologies Corporation$61.94Mreported value-3.26M shares

Exited positions

MRNAModerna, Inc.$12.90Mprior reported value-237.2K shares-100.0%SNTISenti Biosciences Holdings, Inc.$365.1Kprior reported value-168.2K shares-100.0%